DON’T accept any JOB HERE

Discussion in 'Radius Health' started by anonymous, Jun 20, 2018 at 4:03 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest


    This
     

  2. anonymous

    anonymous Guest

    They wouldn't.
     
  3. anonymous

    anonymous Guest


    Because it isn’t an option . . . . . . .
     
  4. anonymous

    anonymous Guest

    But the company ISN’T doing a secondary or debt offering (they’re not soliciting anything), so of course investors aren’t giving anything. Investors aren’t being asked to give anything is my point.
     
  5. anonymous

    anonymous Guest

    Radius is POS. Everyone knows it. Titanic is going down.
     
  6. anonymous

    anonymous Guest

    In 2017, publicly traded companies averaged 10.38% Return on Equity. Radius Health's ROE is -92.58%. Even if Radius was soliciting, they're going to have a hard time luring investors with that stat.
     
  7. anonymous

    anonymous Guest

    they didn’t have a problem with the convertible notes debt offering. I don’t work for the company, I don’t pretend to know what’s going on behind the scenes, but come on, don’t make stuff up, that’s easily disproved (not you, the original commenter).
     
  8. anonymous

    anonymous Guest

    Lilly reps don’t need to comment on this company. Our own reps have enough shitty feelings they do it all themselves! Lol
     
  9. anonymous

    anonymous Guest

    There will a lot of backlash if Radius tries to raise capital again through public offering. Current share holders are max'd out on their tolerance of the dilition of their shares. Wall street will bite back when that time comes.
     
  10. anonymous

    anonymous Guest

    Dilution of their shares I meant.
     
  11. anonymous

    anonymous Guest

    Radius is propped up on sand (to give the best analogy)
     
  12. anonymous

    anonymous Guest

    Still yet to provide any facts.. just the same claim... worded differently with no evidence or substance.
     
  13. anonymous

    anonymous Guest

    How do you know how current shareholders are feeling or what their sentiments are?
     
  14. anonymous

    anonymous Guest

    More like yellow snow and brown droppings
     
  15. anonymous

    anonymous Guest

    For the three months ended March 31, 2018, Radius reported a net loss of $61.6 million, or $1.37 per share, compared to a net loss of $56.9 million, or $1.32 per share, for the three months ended March 31, 2017.

    For the three months ended March 31, 2018, Radius reported TYMLOS net product revenues of $14.5 million compared to zero TYMLOS revenue in the three months ended March 31, 2017.
     
  16. anonymous

    anonymous Guest

    Now that’s promising. Go losers.
     
  17. anonymous

    anonymous Guest

    nobody’s disputing that the company is losing money, but new drug launches and profitability take time, no?

    But to say investors aren’t giving the company anything when they’re not even being solicited/asked is just ridiculous.
     
  18. anonymous

    anonymous Guest

    Face it. This company is shit!
     
  19. anonymous

    anonymous Guest

    Pee Pee will save us. He is a finaicial wizard and a legal immigrant